Abstract

Ciplukan (Physalis angulata Linn.) is a Solanaceae family species and contains various active compounds with diverse therapeutic potential. The goal of this investigation was to see if the ethyl acetate fraction of ciplukan had an antifibrotic impact on liver fibrosis. The oral administration of 20% carbon tetrachloride (CCl4) twice weekly for 8 weeks was used to cause liver fibrosis. Four weeks following fibrosis induction, ciplukan ethyl acetate fractions of 1.11 mg (CPL-1) and 2.22 mg (CPL-2) were given orally. As a positive control group, vitamin E was used. When compared to the negative control, the ethyl acetate portion of 2.22 mg (CPL-2) lowered serum alanine aminotransaminase levels (83.95 ± 27.675 vs 175.23 ± 5.641, p-value < 0.05). Microscopic histopathological changes based on the better Metavir score (CPL-2 vs. negative control = 1.25 ± 1.893 vs. 3.50 ± 0.577; p-value < 0.05) and Ishak score (CPL-2 vs. negative control = 1.50 ± 1.000 vs. 4.75 ± 0.957 p-value < 0.05) were demonstrated. Overall, in rat liver fibrosis induced by CCl4, these findings suggest that the ethyl acetate fraction of ciplukan has an antifibrotic effect

Key words: Physalis angulata Linn., antifibrotic, carbon tetrachloride, liver fibrosis, alanine aminotransferase serum, histopathological changes